A Zantac lawsuit is a legal claim for financial compensation by plaintiffs who took the heartburn medication and were later diagnosed with cancer. Zantac (and the generic version ranitidine) contained the carcinogen NDMA. Studies have linked this hepatotoxin to cancer in both animals and humans.
In the current 2022 litigation, plaintiffs allege that Zantac makers placed a dangerous product on the market and failed to warn consumers of the serious risks and side effects. On April 1, 2020, the U.S. Food and Drug Administration (FDA) requested that all companies withdraw their ranitidine products.
The FDA had found “unacceptable amounts” of NDMA in the ingredient ranitidine. Since then, more than a dozen pharmaceutical companies have recalled the drug.
The ranitidine lawsuits are not part of a class action. Instead, these are individual lawsuits of the victim against the drugmaker. Many of the claims will join into multidistrict litigation (MDL). This will expedite the litigation and settlement process.
Who qualifies for Zantac lawsuits?
In terms of case criteria, our firm is accepting cases where the person took Zantac– or a combination of Zantac and ranitidine – for at least once a week for a minimum of one year and afterwards was diagnosed with any of the following five types of cancer:
Consumer Help Group. All rights reserved © 2022 Made by OXX LEADS
